DAX22.513 -0,4%ESt505.493 -0,1%Top 10 Crypto14,91 +4,4%Dow44.546 -0,4%Nas20.027 +0,4%Bitcoin92.961 +0,1%Euro1,0493 ±0,0%Öl74,64 -0,9%Gold2.884 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 BASF BASF11 Tesla A1CX3T Commerzbank CBK100 Volkswagen (VW) vz. 766403 Mercedes-Benz Group (ex Daimler) 710000 Siemens Energy ENER6Y BYD A0M4W9 Siemens 723610 Allianz 840400 Deutsche Telekom 555750 Palantir A2QA4J Bayer BAY001 RENK RENK73
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen schließen mit uneinheitlicher Tendenz -- DAX geht etwas leichter ins Wochenende -- NVIDIAs Depot in Q4 -- Moderna mit massiven Verlusten -- Coinbase, Arm, Palo Alto, Rheinmetall im Fokus
Top News
Goldpreis, Ölpreis & Co. - So performten Rohstoffe in KW 7 Goldpreis, Ölpreis & Co. - So performten Rohstoffe in KW 7
Die Highlights im TecDAX: Tops und Flops der KW 7 im Überblick Die Highlights im TecDAX: Tops und Flops der KW 7 im Überblick
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Dignify Therapeutics Highlights Clinical Development Plans at BIO CEO & Investor Conference

14.02.25 20:34 Uhr

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2025 /PRNewswire/ -- Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with neurological conditions, presented its clinical development plans for its lead assets, DTI-117 and DTI-301, at the BIO CEO & Investor Conference held in New York on February 10-11, 2025.

Dignify Therapeutics logo (PRNewsfoto/Dignify Therapeutics)

During the conference, Dignify CEO Anthony DiTonno provided an update of the company's progress and strategic direction. He emphasized Dignify Therapeutics' commitment to developing innovative therapies for individuals affected by spinal cord injuries, diabetes, Parkinson's disease, and other neurological conditions.

DTI-301 and DTI-117 are at the forefront of the company's pipeline and are treatments for bladder and bowel dysfunction associated with neurological conditions and the aging process. Currently, many of these individuals require bladder catheterization for bladder emptying and an invasive, time-consuming manual bowel program for bowel evacuation.

Dignify's lead drug program, DTI-301, is a suppository that patients use as needed for bowel evacuation. DTI-301 induces defecation within 5-10 minutes, with minimal absorption and systemic exposure. Dignify's second drug program, DTI-117, is currently in development for on-demand emptying of both the bladder and bowel. DTI-117 directly stimulates smooth muscle contraction in the bladder and bowel, produces voiding in less than 10 minutes, and is rapidly eliminated from the body.

About Dignify Therapeutics
Dignify Therapeutics is a biotechnology company focused on developing therapies to restore voluntary bowel and bladder function in individuals with neurological conditions. The company's mission is to improve the quality of life for individuals affected by neurological disorders, and the elderly.
For more information about Dignify Therapeutics and its clinical development programs, please visit www.dignifytherapeutics.com.

About the BIO CEO & Investor Conference
The BIO CEO & Investor Conference serves as a premier platform for biotech companies to engage with investors and industry leaders, fostering discussions on the latest advancements and investment opportunities in the biotechnology sector.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dignify-therapeutics-highlights-clinical-development-plans-at-bio-ceo--investor-conference-302377304.html

SOURCE Dignify Therapeutics